Bioasis is dedicated to delivering hope to patients suffering with neurological diseases and disorders. Our breakthrough science focuses on transporting medicines across the blood-brain barrier, providing a path to hundreds of previously untreatable diseases of the central nervous system.
Bioasis Announces Stock Option GrantsJul. 17, 2019
Bioasis Announces FDA Response to Pre-IND SubmissionJun. 25, 2019
Bioasis Announces Allowances of Patent Applications in the U.S. and Europe Relating to xB3 Platform Technology and Key Therapeutic IndicationsJun. 24, 2019
U.S. Patent Office and European Patent Office issue allowances of patent applications relating to iduronate-2-sulfatase (“IDS”) polypeptide/xB3 conjugates European Patent Office issues allowance of patent application relating to trastuzumab/xB3 conjugates including xB3-001, Bioasis’ lead product in development for the treatment of HER2+ breast cancer brain metastases